Breeden v. Novartis Pharmaceuticals Corp.

181 L. Ed. 2d 981, 132 S. Ct. 1116, 565 U.S. 1158, 2012 U.S. LEXIS 853, 80 U.S.L.W. 3425, 2012 WL 117582
CourtSupreme Court of the United States
DecidedJanuary 17, 2012
DocketNo. 11-669
StatusPublished

This text of 181 L. Ed. 2d 981 (Breeden v. Novartis Pharmaceuticals Corp.) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Breeden v. Novartis Pharmaceuticals Corp., 181 L. Ed. 2d 981, 132 S. Ct. 1116, 565 U.S. 1158, 2012 U.S. LEXIS 853, 80 U.S.L.W. 3425, 2012 WL 117582 (U.S. 2012).

Opinion

Petition for writ of certiorari to the United States Court of Appeals for the District of Columbia Circuit denied.

Same case below, 396 U.S. App. D.C. 170, 646 F.3d 43.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Breeden v. Novartis Pharmaceuticals Corp.
646 F.3d 43 (D.C. Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
181 L. Ed. 2d 981, 132 S. Ct. 1116, 565 U.S. 1158, 2012 U.S. LEXIS 853, 80 U.S.L.W. 3425, 2012 WL 117582, Counsel Stack Legal Research, https://law.counselstack.com/opinion/breeden-v-novartis-pharmaceuticals-corp-scotus-2012.